873225-46-8

Basic information

• Product Name: IKK 16
• Synonyms: IKK Inhibitor;[4-[(4-Benzo[b]thien-2-yl-2-pyriMidinyl)aMino]phenyl][4-(1-pyrrolidinyl)-1-piperidinyl]-Methanone;1-[4-[(4-Benzo[b]thien-2-yl-2-pyrimidinyl)amino]benzoyl]-4-(1-pyrrolidinyl)piperidine;IKK Inhibitor VII;Methanone, [4-[(4-benzo[b]thien-2-yl-2-pyrimidinyl)amino]phenyl][4-(1-pyrrolidinyl)-1-piperidinyl]-;1-[4-[(4-Benzo[b]thien-2-yl-2-pyrimidinyl)amino]benzoyl]-4-(1-pyrrolidinyl)piperidine IKK-16 (IKK Inhibitor VII)
• CAS NO: 873225-46-8
• Molecular Formula: C28H29N5OS
• Molecular Weight: 483.62776
• Product Categories: IκB/IKK;Aromatics, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals, Sulfur & Selenium Compounds;Inhibitors;NF-kB
• Mol File: 873225-46-8.mol

Chemical Properties

• Appearance: /
• Solubility: ≥23.05 mg/mL in DMSO; ≥11.3 mg/mL in EtOH with ultrasonic; insoluble in H2O
• CAS DataBase Reference: IKK 16(CAS DataBase Reference)
• NIST Chemistry Reference: IKK 16(873225-46-8)
• EPA Substance Registry System: IKK 16(873225-46-8)

Safety Data

• Hazardous Substances Data: 873225-46-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
IKK 16 is used as an IKK2 inhibitor for the treatment of various immune/inflammatory disorders. Its ability to modulate the immune response makes it a promising candidate for the development of therapeutic agents targeting conditions such as rheumatoid arthritis, inflammatory bowel disease, and other autoimmune disorders.

Biological Activity

ikk-16 (ikk inhibitor vii) is a novel inhibitor of iκb kinase (ikk) with the ic50 values of 0.04μm, 0.2μm and 0.07μm for ikk2, ikk1 and ikk complex, respectively [1].ikk-16 (ikk inhibitor vii) is a 2-benzamido-pyrimidines and selective inhibitor of iκb kinase (ikk). ikk-16 has been reported to effectively inhibit tnfα release into plasma upon lps-challenge in the rat. in addition, ikk-16 has been found to be active at thioglycollate-induced peritonitis model in the mouse. furthermore, ikk-16 has revealed to be an orally bio-available in rats and mice, and have significant in vivo activity in an acute model of cytokine release [1].

references

[1] waelchli r1, bollbuck b, bruns c, buhl t, eder j, feifel r, hersperger r, janser p, revesz l, zerwes hg, schlapbach a.design and preparation of 2-benzamido-pyrimidines as inhibitors of ikk. bioorg med chem lett. 2006 jan 1;16(1):108-12. epub 2005 oct 19.

Upstream product

• 873225-37-7 4-(4-benzo[b]thiophen-2-yl-pyrimidin-2-ylamino)-benzoyl chloride 
• 5004-07-9 4-(1-pyrrolidinyl)piperidine 
• 124959-26-8 4-(2'-benzothienyl)-2-chloropyrimidine 
• 98437-23-1 benzo[b]thiophene-2-boronic acid 
• 873225-34-4 4-(4-benzo[b]thiophen-2-yl-pyrimidin-2-ylamino)-benzoic acid methyl ester 
• 873225-30-0 4-(4-benzo[b]thiophen-2-yl-pyrimidin-2-ylamino)-benzoic acid 

Relevant articles and documents

Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK

The design, synthesis, and the biological evaluation of 2-benzamido-pyrimidines as novel IKK inhibitors are described. By optimization of the lead compound 3, compounds 16 and 24 are identified as good inhibitors of IKK2 with IC50 values of 40 and 25 nM, respectively. Compound 16 also demonstrated significant in vivo activity in an acute model of cytokine release.